Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide and Neuroprotection in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prematurity (birthweight ≤ 1500g, \< 31 weeks gestation)~* Requiring respiratory support~* Admitted to the NICU at the University of Chicago~Exclusion Criteria:~* Severe congenital anomalies~* Genetic syndromes~* Extremely sick preterm infants requiring very high ventilatory pressures (OI ≥ 20)~* Premature infants judged by the physician as nonviable

- Gender: ALL
- Minimum Age: 2 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- INO Control (Short iNO) (Type: PLACEBO_COMPARATOR): INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
- INO Treatment (Long iNO) (Type: EXPERIMENTAL): The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.

Based on this trial design, predict the completion outcome and termination type (if applicable).